FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2935804657> ?p ?o ?g. }

• W2935804657 endingPage "2906" @default.
• W2935804657 startingPage "2888" @default.
• W2935804657 abstract "Because of its role in mediating both B cell and Fc receptor signaling, Bruton's tyrosine kinase (BTK) is a promising target for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Evobrutinib is a novel, highly selective, irreversible BTK inhibitor that potently inhibits BCR- and Fc receptor-mediated signaling and, thus, subsequent activation and function of human B cells and innate immune cells such as monocytes and basophils. We evaluated evobrutinib in preclinical models of RA and SLE and characterized the relationship between BTK occupancy and inhibition of disease activity. In mouse models of RA and SLE, orally administered evobrutinib displayed robust efficacy, as demonstrated by reduction of disease severity and histological damage. In the SLE model, evobrutinib inhibited B cell activation, reduced autoantibody production and plasma cell numbers, and normalized B and T cell subsets. In the RA model, efficacy was achieved despite failure to reduce autoantibodies. Pharmacokinetic/pharmacodynamic modeling showed that mean BTK occupancy in blood cells of 80% was linked to near-complete disease inhibition in both RA and SLE mouse models. In addition, evobrutinib inhibited mast cell activation in a passive cutaneous anaphylaxis model. Thus, evobrutinib achieves efficacy by acting both on B cells and innate immune cells. Taken together, our data show that evobrutinib is a promising molecule for the chronic treatment of B cell-driven autoimmune disorders." @default.
• W2935804657 created "2019-04-25" @default.
• W2935804657 creator A5002425824 @default.
• W2935804657 creator A5004108054 @default.
• W2935804657 creator A5004870686 @default.
• W2935804657 creator A5006243364 @default.
• W2935804657 creator A5025232794 @default.
• W2935804657 creator A5026407279 @default.
• W2935804657 creator A5034158449 @default.
• W2935804657 creator A5043402291 @default.
• W2935804657 creator A5053210580 @default.
• W2935804657 creator A5059472140 @default.
• W2935804657 creator A5068489786 @default.
• W2935804657 creator A5085444021 @default.
• W2935804657 date "2019-04-15" @default.
• W2935804657 modified "2023-10-18" @default.
• W2935804657 title "Efficacy and Pharmacodynamic Modeling of the BTK Inhibitor Evobrutinib in Autoimmune Disease Models" @default.
• W2935804657 cites W1508090369 @default.
• W2935804657 cites W1538100539 @default.
• W2935804657 cites W1567332472 @default.
• W2935804657 cites W1590814315 @default.
• W2935804657 cites W1670985771 @default.
• W2935804657 cites W1813485308 @default.
• W2935804657 cites W1891620832 @default.
• W2935804657 cites W1964591874 @default.
• W2935804657 cites W1968104064 @default.
• W2935804657 cites W1977054868 @default.
• W2935804657 cites W1988928788 @default.
• W2935804657 cites W1993345471 @default.
• W2935804657 cites W2001343785 @default.
• W2935804657 cites W2003164049 @default.
• W2935804657 cites W2005524204 @default.
• W2935804657 cites W2011960630 @default.
• W2935804657 cites W2012594643 @default.
• W2935804657 cites W2015521668 @default.
• W2935804657 cites W2020857813 @default.
• W2935804657 cites W2025755006 @default.
• W2935804657 cites W2025851689 @default.
• W2935804657 cites W2032362610 @default.
• W2935804657 cites W2033867789 @default.
• W2935804657 cites W2035825766 @default.
• W2935804657 cites W2037306256 @default.
• W2935804657 cites W2039194398 @default.
• W2935804657 cites W2052690081 @default.
• W2935804657 cites W2057605053 @default.
• W2935804657 cites W2067064694 @default.
• W2935804657 cites W2071562052 @default.
• W2935804657 cites W2077950012 @default.
• W2935804657 cites W2078066300 @default.
• W2935804657 cites W2078275018 @default.
• W2935804657 cites W2080919674 @default.
• W2935804657 cites W2081684575 @default.
• W2935804657 cites W2089103836 @default.
• W2935804657 cites W2091347081 @default.
• W2935804657 cites W2091395656 @default.
• W2935804657 cites W2093522627 @default.
• W2935804657 cites W2098657513 @default.
• W2935804657 cites W2100034730 @default.
• W2935804657 cites W2108011476 @default.
• W2935804657 cites W2108485092 @default.
• W2935804657 cites W2112067801 @default.
• W2935804657 cites W2113764179 @default.
• W2935804657 cites W2115629214 @default.
• W2935804657 cites W2122685956 @default.
• W2935804657 cites W2132472913 @default.
• W2935804657 cites W2140458881 @default.
• W2935804657 cites W2142604595 @default.
• W2935804657 cites W2154692796 @default.
• W2935804657 cites W2157486761 @default.
• W2935804657 cites W2159932847 @default.
• W2935804657 cites W2162387968 @default.
• W2935804657 cites W2163431182 @default.
• W2935804657 cites W2163690533 @default.
• W2935804657 cites W2163881620 @default.
• W2935804657 cites W2166422945 @default.
• W2935804657 cites W2166706442 @default.
• W2935804657 cites W2167854315 @default.
• W2935804657 cites W2171771895 @default.
• W2935804657 cites W2250687747 @default.
• W2935804657 cites W2258682798 @default.
• W2935804657 cites W2268416727 @default.
• W2935804657 cites W2288361228 @default.
• W2935804657 cites W2339207738 @default.
• W2935804657 cites W2419653009 @default.
• W2935804657 cites W2604548019 @default.
• W2935804657 cites W2604620912 @default.
• W2935804657 cites W2738325237 @default.
• W2935804657 cites W2760270300 @default.
• W2935804657 cites W2788286120 @default.
• W2935804657 cites W2788356134 @default.
• W2935804657 cites W2790933581 @default.
• W2935804657 cites W2805328067 @default.
• W2935804657 cites W2938377847 @default.
• W2935804657 cites W1966315656 @default.
• W2935804657 doi "https://doi.org/10.4049/jimmunol.1800583" @default.
• W2935804657 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6500888" @default.
• W2935804657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30988116" @default.
• W2935804657 hasPublicationYear "2019" @default.

• next